{
    "name": "riluzole",
    "comment": "Rx",
    "other_names": [
        "Rilutek",
        "Tiglutik",
        "Exservan"
    ],
    "classes": [
        "Glutamate Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/tiglutik-rilutek-riluzole-343067",
    "pregnancy": {
        "common": [
            "There are no studies in pregnant women, and case reports have been inadequate to inform of drug-associated risk",
            "Unknown if risk of major birth defects and miscarriage in patients with amyotrophic lateral sclerosis"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In studies in which riluzole was orally administered to pregnant animals, developmental toxicity (decreased embryofetal/offspring viability, growth, and functional development) was observed at clinically relevant doses",
                    "Based on these results, advise women of possible risks to fetus associated with use of riluzole during pregnancy",
                    "In rats, oral administration of riluzole resulted in decreased fertility indices and increases in embryo lethality"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "Riluzole or its metabolites have been detected in milk of lactating rat",
            "Consider the developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to drug or any component of the formulation"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Cases of severe neutropenia (absolute neutrophil count <500/mm",
                "3",
                ") within first 2 months of treatment reported; advise patients to report febrile illnesses",
                "Interstitial lung disease, including hypersensitivity pneumonitis, reported in patients receiving therapy; discontinue immediately if interstitial lung disease develops"
            ],
            "specific": [
                {
                    "type": "Hepatic injury",
                    "description": [
                        "Cases of drug-induced liver injury reported; asymptomatic elevations of hepatic transaminases reported and recurred in some patients upon rechallenging treatment (see Dosage Modifications)",
                        "Monitor patients for signs and symptoms of hepatic injury, every month for first 3 months of treatment, and periodically thereafter; use is not recommended if patients develop hepatic transaminase levels greater than 5 times the ULN; discontinue therapy if there is evidence of liver dysfunction (eg, elevated bilirubin)",
                        "Case reports of clinical hepatitis reported"
                    ]
                },
                {
                    "type": "Drug interactions overview",
                    "description": [
                        "Riluzole is a CYP1A substrate",
                        "CYP1A2 inhibitors",
                        "In vitro findings suggest coadministration of riluzole with CYP1A2 inhibitors may increase in riluzole exposure",
                        "Coadministration with strong or moderate CYP1A2 inhibitors (eg, ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) may increase risk of riluzole-associated adverse reactions",
                        "CYP1A2 inducers",
                        "In vitro findings suggest coadministration with CYP1A2 inducers may decrease in riluzole exposure, which may result in decreased efficacy",
                        "Hepatotoxic drugs",
                        "Clinical trials in ALS patients excluded patients on concomitant medications which were potentially hepatotoxic (eg, allopurinol, methyldopa, sulfasalazine)"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP1A2 substrates. If not feasible, avoid use of abametapir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "givosiran",
            "description": {
                "common": "givosiran will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP1A2 substrates with givosiran. If unavoidable, decrease the CYP1A2 substrate dosage in accordance with approved product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leniolisib",
            "description": {
                "common": "leniolisib will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid leniolisib with CYP1A2 substrates that have a narrow therapeutic index"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupivacaine implant",
            "description": {
                "common": "riluzole, bupivacaine implant.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Local anesthetics may increase the risk of developing methemoglobinemia when concurrently exposed to drugs that also cause methemoglobinemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cannabidiol",
            "description": {
                "common": "cannabidiol, riluzole. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "ciprofloxacin will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and riluzole both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pefloxacin",
            "description": {
                "common": "pefloxacin will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rucaparib",
            "description": {
                "common": "rucaparib will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP1A2 substrates, if clinically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, riluzole. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP1A2 inhibitor and inducer. Monitor CYP1A2 substrates coadministered with stiripentol for increased or decreased effects. CYP1A2 substrates may require dosage adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "teriflunomide",
            "description": {
                "common": "teriflunomide decreases levels of riluzole by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital will decrease the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "armodafinil",
            "description": {
                "common": "armodafinil will decrease the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital will decrease the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital will decrease the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cigarette smoking",
            "description": {
                "common": "cigarette smoking will decrease the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cimetidine",
            "description": {
                "common": "cimetidine will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "erythromycin base will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "erythromycin ethylsuccinate will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "erythromycin lactobionate will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "erythromycin stearate will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "food",
            "description": {
                "common": "food decreases levels of riluzole by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mexiletine",
            "description": {
                "common": "mexiletine will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "modafinil",
            "description": {
                "common": "modafinil will decrease the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "omeprazole",
            "description": {
                "common": "omeprazole will decrease the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "peginterferon alfa 2a",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital will decrease the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pipemidic acid",
            "description": {
                "common": "pipemidic acid will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital will decrease the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "smoking",
            "description": {
                "common": "smoking will decrease the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tobacco use",
            "description": {
                "common": "tobacco use will decrease the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "verapamil",
            "description": {
                "common": "verapamil will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "zileuton",
            "description": {
                "common": "zileuton will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Oral hypoesthesia",
            "percent": "29"
        },
        {
            "name": "Asthenia",
            "percent": "19"
        },
        {
            "name": "Nausea",
            "percent": "16"
        },
        {
            "name": "Decreased lung function",
            "percent": "10"
        },
        {
            "name": "Hypertension",
            "percent": "5"
        },
        {
            "name": "Abdominal pain",
            "percent": "5"
        },
        {
            "name": "Vomiting",
            "percent": "4"
        },
        {
            "name": "Arthralgia",
            "percent": "4"
        },
        {
            "name": "Dizziness",
            "percent": "4"
        },
        {
            "name": "Dry mouth",
            "percent": "4"
        },
        {
            "name": "Insomnia",
            "percent": "4"
        },
        {
            "name": "Pruritus",
            "percent": "4"
        },
        {
            "name": "Tachycardia",
            "percent": "3"
        },
        {
            "name": "Flatulence",
            "percent": "3"
        },
        {
            "name": "Increased cough",
            "percent": "3"
        },
        {
            "name": "Peripheral edema",
            "percent": "3"
        },
        {
            "name": "Urinary tract infection",
            "percent": "3"
        },
        {
            "name": "Circumoral paresthesia",
            "percent": "2"
        },
        {
            "name": "Somnolence",
            "percent": "2"
        },
        {
            "name": "Vertigo",
            "percent": "2"
        },
        {
            "name": "Eczema",
            "percent": "2"
        },
        {
            "name": "Acute hepatitis",
            "percent": null
        },
        {
            "name": "Icteric toxic hepatitis",
            "percent": null
        },
        {
            "name": "Renal tubular impairment",
            "percent": null
        },
        {
            "name": "Pancreatitis",
            "percent": null
        }
    ]
}